Search

Your search keyword '"Hashine, Katsuyoshi"' showing total 214 results
Start Over Author "Hashine, Katsuyoshi" Publication Type Academic Journals
214 results on '"Hashine, Katsuyoshi"'

3. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

Author

Shiota, Masaki, Miyake, Hideaki, Takahashi, Masayuki, Oya, Mototsugu, Tsuchiya, Norihiko, Masumori, Naoya, Matsuyama, Hideyasu, Obara, Wataru, Shinohara, Nobuo, Fujimoto, Kiyohide, Nozawa, Masahiro, Ohba, Kojiro, Ohyama, Chikara, Hashine, Katsuyoshi, Akamatsu, Shusuke, Kamba, Tomomi, Mita, Koji, Gotoh, Momokazu, Tatarano, Shuichi, Fujisawa, Masato, Tomita, Yoshihiko, Mukai, Shoichiro, Ito, Keiichi, Tanegashima, Tokiyoshi, Tokunaga, Shoji, and Eto, Masatoshi

Published
2023
Full Text
View/download PDF

4. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data

Author

Tomida, Ryotaro, Miyake, Makito, Minato, Ryoei, Sawada, Yuichiro, Matsumura, Masafumi, Iida, Kota, Hori, Shunta, Fukui, Shinji, Ohyama, Chikara, Miyake, Hideaki, Hongo, Fumiya, Taoka, Rikiya, Kobayashi, Takashi, Kojima, Takahiro, Matsui, Yoshiyuki, Nishiyama, Naotaka, Kitamura, Hiroshi, Nishiyama, Hiroyuki, Fujimoto, Kiyohide, and Hashine, Katsuyoshi

Published
2022
Full Text
View/download PDF

5. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN

Author

Kato, Takuma, Hirama, Hiromi, Mitsuzuka, Koji, Maruyama, Satoru, Sasaki, Hiroshi, Saito, Toshihiro, Matsumoto, Ryuji, Sakamoto, Shinichi, Sakai, Yasuyuki, Fukuhara, Hiroshi, Naya, Yukio, Tsukino, Hiromasa, Hara, Isao, Ogawa, Osamu, Hashine, Katsuyoshi, Fumimasa, Fukuta, Yokomizo, Akira, Tohi, Yoichiro, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

6. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Nakamura, Masaki, Matsumoto, Ryuji, Sasaki, Hiroshi, Mitsuzuka, Koji, Inokuchi, Junichi, Hashine, Katsuyoshi, Yokomizo, Akira, Naito, Hirohito, Hara, Isao, Kawamura, Norihiko, Inoue, Masaharu, Fukuhara, Hiroshi, Maruyama, Satoru, Sakamoto, Shinichi, Saito, Toshihiro, Egawa, Shin, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

8. Validation study on the 2 mm diameter cutoff in lymph node‐positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real‐world data analysis from a Japanese cohort.

Author

Kato, Masashi, Shiota, Masaki, Kimura, Takahiro, Hanazawa, Ryoichi, Hirakawa, Akihiro, Takamatsu, Dai, Tashiro, Kojiro, Matsui, Yoshiyuki, Hashine, Katsuyoshi, Saito, Ryoichi, Yokomizo, Akira, Yamamoto, Yoshiyuki, Narita, Shintaro, Hashimoto, Kohei, Matsumoto, Hiroaki, Akamatsu, Shusuke, Nishiyama, Naotaka, Eto, Masatoshi, Kitamura, Hiroshi, and Tsuzuki, Toyonori

Subjects
RADICAL prostatectomy, MICROMETASTASIS, PROSTATE cancer, CANCER patients, PROSTATE cancer patients, LYMPHATIC metastasis, DATA analysis
Abstract

Objectives: The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 8th edition has proposed micrometastasis as a lymph node metastasis (LN+) of diameter ≤2 mm in prostate cancer. However, supporting evidence has not described. We evaluated LN+ patients' survival after radical prostatectomy (RP) based on the LN maximum tumor diameter (MTD). Methods: Data from 561 LN+ patients after RP and pelvic LN dissection (PLND) treated between 2006 and 2019 at 33 institutions were retrospectively investigated. Patients were stratified by a LN+ MTD cutoff of 2 mm. Outcomes included castration resistance‐free survival (CRFS), metastasis‐free survival (MFS), cancer‐specific survival (CSS), and overall survival (OS). Results: In total, 282 patients were divided into two groups (LN+ MTD >2 mm [n = 206] and ≤2 mm [n = 76]). Patients of LN+ status >2 mm exhibited significantly decreased CRFS and MFS, and poorer CSS and OS. No patients developed CRPC in the LN+ status ≤2 mm group when the PLND number was ≥14. Multivariate analysis showed the number of LN removed, RP Gleason pattern 5, and MTD in LN+ significantly predicted CRFS. Conclusions: Patients of LN+ status ≤2 mm showed better prognoses after RP. In all the patients in the ≤2‐mm group, the progression to CRPC could be prevented with appropriate interventions, particularly when PLND is performed accurately. Our findings support the utility of the pN substaging proposed by the AJCC/UICC 8th edition; this will facilitate precision medicine for patients with advanced prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN

Author

Hirama, Hiromi, Sugimoto, Mikio, Miyatake, Nobuyuki, Kato, Takuma, Venderbos, Lionne D. F., Remmers, Sebastiaan, Shiga, Kenichiro, Yokomizo, Akira, Mitsuzuka, Koji, Matsumoto, Ryuji, Osawa, Takahiro, Abe, Takashige, Sasaki, Hiroshi, Egawa, Shin, Ninomiya, Iku, Hashine, Katsuyoshi, Roobol, Monique J., and Kakehi, Yoshiyuki

Published
2021
Full Text
View/download PDF

10. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

11. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Matsumoto, Ryuji, Shinohara, Nobuo, Shiga, Kenichiro, Yokomizo, Akira, Nakamura, Masaki, Kume, Haruki, Mitsuzuka, Koji, Sasaki, Hiroshi, Egawa, Shin, Matsumura, Masafumi, Hashine, Katsuyoshi, Inokuchi, Junichi, Eto, Masatoshi, Baba, Haruki, Ichikawa, Tomohiko, Kinoshita, Hidefumi, Matsuda, Tadashi, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2020
Full Text
View/download PDF

13. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

15. Correction to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

Author

Tohi, Yoichiro, Kato, Takuma, Matsumoto, Ryuji, Shinohara, Nobuo, Shiga, Kenichiro, Yokomizo, Akira, Nakamura, Masaki, Kume, Haruki, Mitsuzuka, Koji, Sasaki, Hiroshi, Egawa, Shin, Matsumura, Masafumi, Hashine, Katsuyoshi, Inokuchi, Junichi, Eto, Masatoshi, Baba, Haruki, Ichikawa, Tomohiko, Kinoshita, Hidefumi, Matsuda, Tadashi, Kakehi, Yoshiyuki, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

17. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

18. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study.

Author

Blas, Leandro, Shiota, Masaki, Miyake, Hideaki, Takahashi, Masayuki, Oya, Mototsugu, Tsuchiya, Norihiko, Masumori, Naoya, Matsuyama, Hideyasu, Obara, Wataru, Shinohara, Nobuo, Fujimoto, Kiyohide, Nozawa, Masahiro, Ohba, Kojiro, Ohyama, Chikara, Hashine, Katsuyoshi, Akamatsu, Shusuke, Kamba, Tomomi, Mita, Koji, Gotoh, Momokazu, and Tatarano, Shuichi

Subjects
NIVOLUMAB, KARNOFSKY Performance Status, PROGNOSIS, JAPANESE people, PROGRESSION-free survival, RENAL cell carcinoma
Abstract

Background: This study is part of the SNPs in Nivolumab PD‐1 inhibitor for RCC (SNiP‐RCC). Here we aimed to reveal clinical factors for tumor response, progression, and survival in nivolumab for advanced clear cell renal cell carcinoma (RCC) in Japanese patients. Methods: We included patients from 23 institutions in Japan. We evaluated the objective response, radiographic progression‐free survival (PFS), overall survival (OS), and treatment‐related grade ≥ 3 (serious adverse events [SAEs]). Results: We included 222 patients. The median age was 69 years (interquartile range 62–74 years), and 71% of the patients were male. Pancreas metastasis, lung metastases, prior cytokine therapy, and SAEs, were associated with objective response. The median PFS was 18 months. Liver metastases (hazard ratio [HR], 1.61), age ≥ 75 (HR, 0.48), previous resection of primary sites (HR, 0.47), and SAEs (HR, 0.47) were independent prognostic factors for PFS. Karnofsky Performance Status <70 (HR, 2.90), high platelets (HR, 4.48), previous resection of primary sites (HR, 0.23), and pathological grade (HR, 0.19 for grade 2 and HR, 0.12 for grade 3) were independent prognostic factors for OS. SAEs were reported in 45 (20.3%) cases. In the group of patients with prior nephrectomy, SAEs were associated with objective response, PFS, and OS. Conclusion: The SNiP‐RCC study identified clinical parameters correlated with treatment outcomes in Japanese patients with priorly treated advanced clear cell RCC undergoing nivolumab monotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Radical prostatectomy trends between 2010 and 2020 in Ehime, Japan, identified using data from the Medical Investigation Cancer Network (MICAN) study.

Author

Hashine, Katsuyoshi, Yamashita, Natsumi, Tachou, Takatoshi, Kan, Masaharu, Yanagaki, Takahiro, Oka, Akihiro, Takeda, Hajime, Shirato, Akitomi, Watanabe, Uichi, Miura, Noriyoshi, and Saika, Takashi

Subjects
*RADICAL prostatectomy, *HEALTH facilities, *PROSTATE biopsy, *RETROPUBIC prostatectomy, *SURGICAL robots, *PROSTATE cancer
Abstract

Objectives: The use of radical prostatectomy is increasing with the rising incidence of prostate cancer. We assessed the surgical trends related to radical prostatectomy using data from a multi‐center, retrospective cohort study, the MICAN (Medical Investigation Cancer Network) study, which was conducted in all the urology‐related medical facilities in Ehime Prefecture, Japan. Methods: We compared data from the MICAN study with prostate biopsy registry data collected in Ehime between 2010 and 2020 and recorded the surgical trends. Results: There was a significant increase in the mean age of patients with positive biopsies, and the positivity rate increased from 46.3% in 2010 to 60.5% in 2020, while the number of biopsies obtained decreased. The number of radical prostatectomies performed increased over the years, with robot‐assisted radical prostatectomy becoming the predominant procedure. In 2020, robot‐assisted radical prostatectomies accounted for 96.0% of the surgeries performed. The age at surgery also gradually increased. Of the registered patients aged ≤75 years, 40.5% underwent surgery in 2010, compared with 83.1% in 2020. The prevalence of surgery also increased from 4.6% to 29.8% in patients aged >75 years. There was a gradual increase in the proportion of high‐risk cases, from 29.3% to 44.0%, but a decrease in that of low‐risk cases, from 23.8% in 2010 to 11.4% in 2020. Conclusions: We have shown that the number of radical prostatectomies performed in Ehime is increasing in patients aged both ≤75 and >75 years. The proportion of low‐risk cases has decreased, while that of high‐risk cases has increased. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Patient-reported outcomes after robot-assisted radical prostatectomy and institutional learning curve for functional outcomes.

Author

Hashine, Katsuyoshi, Tada, Koki, Minato, Ryoei, Sawada, Yuichiro, and Matsumura, Masafumi

Subjects
*RADICAL prostatectomy, *SURGICAL robots, *FUNCTIONAL status, *PROSTATE cancer
Abstract

Purpose: The study was performed to examine patient-reported outcomes (PROs) in the 1st year after surgery and the institutional learning curve after the introduction of robot-assisted radical prostatectomy (RARP). Materials and Methods: The subjects were 320 consecutive patients who underwent RARP from 2014 to 2018. These cases were divided into three groups treated in the early, middle, and late periods, with about 100 cases in each. PROs were recorded using the Expanded Prostate Cancer Index Composite (EPIC). Results: There were no significant differences among the early, middle, and late periods based on EPIC scores. Urinary function and bother decreased in the 1st month after surgery, and gradually recovered thereafter. However, urinary function was significantly worse in the 1st year after surgery than at baseline. Urinary function and bother were better in patients treated with nerve-sparing surgery, and in nerve-sparing cases, urinary function and bother were best in the early period and worst in the late period. These cases also had the best score for sexual function in the early period, but sexual bother was worst in the early period. In contrast, in cases treated without nerve-sparing surgery, urinary function and bother were best in the late period and worst in the early period, although without significant differences. Conclusion: The functional results of this study based on PROs are useful for providing information for patients. Interestingly, the institutional learning curves for RARP differed in cases that did and did not undergo a nerve-sparing procedure. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Predictive factors for the effectiveness of novel androgen receptor axis‐targeted agents in patients with metastatic prostate cancer.

Author

Koshiro, Nishimoto, Nakajima, Kenichi, Oyama, Masafumi, Kaneko, Go, Takahashi, Satoru, Matsuyama, Hideyasu, Shiina, Hiroaki, Ichikawa, Tomohiko, Horikoshi, Hiroyuki, Hashine, Katsuyoshi, Sugiyama, Yutaka, Miyao, Takeshi, Kamiyama, Manabu, Harada, Kenichi, Ito, Akito, and Mizokami, Atsushi

Subjects
ANDROGEN receptors, PROSTATE cancer patients, CASTRATION-resistant prostate cancer, BONE metastasis, RADIONUCLIDE imaging
Abstract

Objective: Novel androgen receptor axis‐targeted agents (ARATAs) have been developed for mCRPC and improved overall survival (OS). Here, we aimed to find predictors who will receive the greatest benefits from ARATAs. Methods: We previously performed a multicenter study to identify prognostic factors for metastatic hormone‐sensitive prostate cancer (mHSPC, n = 148) and mCRPC (n = 99), and showed that the bone scan index (BSI) was one of the significant prognostic factors for 3‐year OS (PROSTAT‐BSI study). mHSPC progressed to mCRPC (n = 101), for which 69 patients were treated with (n = 39) or without ARATAs (n = 30, prior to the approval of ARATAs). The 69 patients were divided into two groups according to patient factors, and these cohorts were further divided into two subgroups by usage of ARATAs. OS was compared between subgroups in each group. Results: The predictors were age (<71.4 years), serum levels of C‐reactive protein (≥0.16 ng/ml) and alkaline phosphatase (≥548 U/L), time to PSA progression after ADT (<8.9 months), the lowest PSA level (≥1 ng/ml) after ADT, and the rate of PSA decline 3 months after ADT (<0.987), whereas hemoglobin levels, PSA before ADT, Gleason scores, existence of visceral metastases, and BSI were not. Conclusions: The present study identified predictors for the effectiveness of ARATAs. The number of bone metastases (≒BSI), existence of visceral metastases, and Gleason scores, which were identified as high‐risk factors in the LATITUDE study and disease volume in CHAARTED criteria, did not appear to be useful for predicting effectiveness from ARATAs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

28. Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

Author

Nishimura, Kazuo, Nonomura, Norio, Hashine, Katsuyoshi, Kanayama, Hiro-omi, Ozono, Seiichiro, Miura, Takeshi, Miki, Tsuneharu, Kakehi, Yoshiyuki, Arai, Yoichi, Ogawa, Osamu, Fujita, Ryuji, Nonomura, Katsuya, Mizokami, Atsushi, Hoshi, Senji, and Akaza, Hideyuki

Published
2013
Full Text
View/download PDF

35. MP01-03 CURRENT TREATMENT PATTERNS AND OUTCOMES OF 109 PATIENTS WITH SEX CORD STROMAL TUMORS IN JAPAN: A MULTI-INSTITUTIONAL STUDY.

Author

Abe, Takashige, Miyai, Kosuke, Tsuzuki, Toyonori, Hashine, Katsuyoshi, Yamashita, Shinichi, Kawahara, Takashi, Nishiya, Naotaka, Kitamura, Hiroshi, Nishiyama, Hiroyuki, Miyata, Haruka, Matusmoto, Ryuji, Osawa, Takahiro, Murai, Sachiyo, and Shinohara, Nobuo

Subjects
GERM cell tumors, TESTIS tumors, GRANULOSA cell tumors, CANCER chemotherapy, CELL tumors, SERTOLI cells, TUMORS
Published
2024
Full Text
View/download PDF

43. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.

Author

Nakajima, Kenichi, Mizokami, Atsushi, Matsuyama, Hideyasu, Ichikawa, Tomohiko, Kaneko, Go, Takahashi, Satoru, Shiina, Hiroaki, Horikoshi, Hiroyuki, Hashine, Katsuyoshi, Sugiyama, Yutaka, Miyao, Takeshi, Kamiyama, Manabu, Harada, Kenichi, and Ito, Akito

Subjects
CASTRATION-resistant prostate cancer, PROSTATE cancer, PROSTATE cancer prognosis, BONE cancer, BONE metastasis, METASTASIS, PROGNOSIS
Abstract

Objective: To determine prognostic factors including the Bone Scan Index in prostate cancer patients receiving standard hormonal therapy and chemotherapy. Methods: This multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index study involved 30 hospitals and enrolled 247 patients (age 71 ± 8 years) with metastatic hormone‐sensitive prostate cancer (n = 148) under hormone therapy and metastatic castration‐resistant prostate cancer (n = 99) under chemotherapy. The Bone Scan Index (%) was determined by whole‐body bone scintigraphy using 99mTc‐methylenediphosphonate. Patients were classified into tertiles and binary groups, and predictors of all‐cause death including Bone Scan Index, prostate‐specific antigen, and bone metabolic markers were determined using survival and proportional hazard analyses. Results: During a mean follow‐up period of 716 ± 404 days, 81 (33%) of the patients died, and 3‐year mortality rates were 20% and 52% in the metastatic hormone‐sensitive prostate cancer and metastatic castration‐resistant prostate cancer groups, respectively. Survival analysis showed that a Bone Scan Index >3.5% was a significant determinant of death in the metastatic hormone‐sensitive prostate cancer group, whereas prostate‐specific antigen >55 ng/mL before chemotherapy was a determinant of prognosis in the metastatic castration‐resistant prostate cancer group. A Bone Scan Index >3.5% was also associated with a high incidence of prostate‐specific antigen progression in the metastatic hormone‐sensitive prostate cancer group. Patients with metastatic hormone‐sensitive prostate cancer and a better Bone Scan Index response (>45%) to treatment had lower mortality rates than those without such response. Conclusion: The Bone Scan Index and hot spot number are significant determinants of 3‐year mortality, and combining the Bone Scan Index with prostate‐specific antigen should contribute to the management of prostate cancer patients with bone metastasis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.

Author

Yokomizo, Akira, Koga, Hirofumi, Ito, Kazuto, Takezawa, Yutaka, Komiyama, Motokiyo, Nishimura, Kazuo, Yonese, Junji, Hashine, Katsuyoshi, Masumori, Naoya, Arai, Gaku, Saito, Shiro, Shinohara, Mitsuru, Shimizu, Nobuaki, Yamauchi, Atsushi, Satoh, Takefumi, Tochigi, Tatsuo, Kobayashi, Mikio, Fujimoto, Hiroyuki, Kakimoto, Ken‐ichi, and Fukui, Iwao

Subjects
HORMONE therapy, EXTERNAL beam radiotherapy, PATIENT reported outcome measures, PROSTATE cancer, ANDROGEN deprivation therapy
Abstract

Background: We evaluated patient‐reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally advanced prostate cancer (Pca). Methods: A multicenter, randomized phase III trial enrolled 303 patients with locally advanced Pca. The patients were treated with 6 months (M) of ADT followed by 72 Gy of EBRT, and were randomly assigned to CADT or IADT after 14 M. The PROs were evaluated at sic points: baseline, 6 M, 8 M, 14 M, 20 M, and 38 M using FACT‐P questionnaires and EPIC urinary, bowel, and sexual bother subscales. Results: The FACT‐P total scores were significantly better (p < 0.05) in IADT versus CADT at 20 M (121.6 vs.115.4) and at 38 M (119.9 vs. 115.2). The physical well‐being scores (PWB) were significantly better (p < 0.05) in IADT versus CADT at 38 M (25.4 vs. 24.0). The functional scores were significantly better in IADT than those in CADT at 14 M (20.2 vs18.7, p < 0.05) and at 20 M (21.0 vs.18.9, p < 0.05). Conclusion: The PRO was significantly favorable in IADT on FACT‐P total score at 20 M and 38 M, PWB and functional scores at 38 M. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.

Author

Inokuchi, Junichi, Kuroiwa, Kentaro, Nishiyama, Hiroyuki, Kojima, Takahiro, Kakehi, Yoshiyuki, Sugimoto, Mikio, Takenaka, Atsushi, Fujimoto, Kiyohide, Yamaguchi, Raizo, Habuchi, Tomonori, Hashine, Katsuyoshi, Mizusawa, Junki, Eba, Junko, Naito, Seiji, Shinohara, N, Masumori, N, Ohyama, C, Ito, A, Kawamura, S, and Tsuchiya, N

Subjects
URINARY organs, TRANSITIONAL cell carcinoma, PROGNOSIS, BLADDER cancer, SURVIVAL analysis (Biometry), URETER diseases
Abstract

Objectives: To investigate the impact on intravesical recurrence and prognosis according to the ureteral ligation timing during radical nephroureterectomy for upper urinary tract urothelial carcinoma. Methods: We carried out a retrospective chart review of 664 patients with non‐metastatic upper urinary tract urothelial carcinoma who underwent radical nephroureterectomy with ureteral ligation (supplementary analysis of JCOG1110A). We excluded patients with previous and/or synchronous bladder cancer, clinically node‐positive disease, no ureteral ligation data, those without ureteral ligation and those with any missing data. We investigated the cumulative incidence of intravesical recurrence and cancer‐specific mortality, and overall survival between patients with ureteral ligation before renovascular ligation (early ureteral ligation), or ureteral ligation after renovascular ligation (late ureteral ligation). Results: Early and late ureteral ligation was carried out in 243 patients (36.6%) and 421 patients (63.4%), respectively. Intravesical recurrence occurred in 218 patients (32.8%) during follow up (median 3.9 years). No significant difference in the intravesical recurrence was found between early and late ureteral ligation groups. Meanwhile, survival in the early ureteral ligation group was significantly worse compared with the late ureteral ligation group. Multivariable analysis showed that early ureteral ligation was an independent prognostic factor for overall survival (hazard ratio 1.88, 95% confidence interval 1.24–2.85, P = 0.003) and cancer‐specific mortality (hazard ratio 1.93, 95% confidence interval 1.14–3.25, P = 0.014). Conclusions: Our findings suggest that the incidence of intravesical recurrence is not affected by the timing of ureteral ligation during radical nephroureterectomy. However, early ureteral ligation might have a negative impact on survival outcomes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results